COO, Alexis Peyroles, recently interviewed by SCRIP’s Lucie Ellis at EBDgroup’s BIOEurope conference

Access to the interview

OSE Immunotherapeutics Presents New Data Analysis Supporting Continued Development of OSE-127 in Inflammatory Bowel Diseases

OSE-127 shown to have significant potential in patients with inflammatory bowel diseases (IBD) in therapeutic escape and with a strong medical need…

 

 

 

OSE Immunotherapeutics Receives a Grant from French Government Program “Fonds Unique Interministériel” to Explore New Cytotoxic Antibodies – Company’s Monoclonal Antibody, OSE-703, to be Significant Focus of Research

The Company will receive a €398,000 grant from the “Fonds Unique Interministériel” (FUI)…

 

OSE Immunotherapeutics to Resume Accrual in Phase 3 Clinical Trial of Tedopi® in Advanced Non-Small Cell Lung Cancer Patients Following Immune Checkpoint Inhibitor Treatment

 

OSE Immunotherapeutics Presenting at the 23rd Annual International Partnering Conference BIO-EUROPE® (Berlin, 6-8 November 2017)

Alexis Peyroles, Chief Operating Officer of OSE Immunotherapeutics, will provide an overview of the Company’s business during the presentation and will participate in one-to-one meetings…

 

OSE Immunotherapeutics Publishes New Data on FR104, CD28-Antagonist Immunotherapy

FR104 shows immune tolerance superiority over CTLA4-Ig in humanized skin transplant model; FR104 efficacious in graft-versus-host reaction in bone marrow transplant model…

 

OSE Immunotherapeutics Presents New Data Strengthening the Rationale of Myeloid Checkpoint Inhibitor OSE-172 as an Immune Cancer Treatment

New ex vivo and preclinical data on its first-in-class checkpoint inhibitor OSE-172 targeting selectively SIRP-alpha, a target expressed on myeloid suppressive cells…

 

OSE Immunotherapeutics Signs a License Option Agreement with Inserm to Develop a New Cancer Immunotherapy Targeting Myeloid Cells

This research collaboration will focus on the development of an antibody that targets a newly identified
C-type lectin receptor…

 

Selexis SA and OSE Immunotherapeutics Expand Strategic Alliance to Further Advance OSE’s OSE-172 and OSE-703 Cancer Immunotherapy Programs

Second and Third Commercial License Agreement Between the Partners Underscore the Advantages of Selexis’ SUREtechnology Platform, Aids OSE Immunotherapeutics Candidates’ Advancement into Clinic…

 

 

 

 

OSE Immunotherapeutics Reports on First-Half 2017 Financial Results and Provides Update on Clinical Advances of its Product Portfolio

OSE Immunotherapeutics Reports on First-Half 2017 Financial Results and Provides Update on Clinical Advances of its Product Portfolio